Atea Pharmaceuticals, Inc. Logo

Atea Pharmaceuticals, Inc.

AVIR

(1.2)
Stock Price

3,37 USD

-34.48% ROA

-33.24% ROE

-1.63x PER

Market Cap.

287.879.020,00 USD

0.43% DER

0% Yield

0% NPM

Atea Pharmaceuticals, Inc. Stock Analysis

Atea Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Atea Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.42x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

Negative ROE (-16.82%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-16.96%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Atea Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Atea Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Atea Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Atea Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2018 0
2019 0 0%
2020 48.633.000 100%
2021 351.367.000 86.16%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Atea Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 6.675.000
2019 10.170.000 34.37%
2020 38.023.000 73.25%
2021 167.205.000 77.26%
2022 81.936.000 -104.07%
2023 112.724.000 27.31%
2023 132.843.000 15.14%
2024 138.784.000 4.28%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Atea Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 2.802.000
2019 4.438.000 36.86%
2020 21.640.000 79.49%
2021 45.785.000 52.74%
2022 48.714.000 6.01%
2023 50.416.000 3.38%
2023 49.919.000 -1%
2024 48.880.000 -2.13%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Atea Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2018 -9.460.000
2019 -14.591.000 35.17%
2020 -11.011.000 -32.51%
2021 138.377.000 107.96%
2022 -130.650.000 205.91%
2023 -162.724.000 19.71%
2023 -119.593.000 -36.06%
2024 -187.248.000 36.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Atea Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2018 -17.000
2019 -17.000 0%
2020 48.614.000 100.03%
2021 351.338.000 86.16%
2022 -260.000 135230%
2023 0 0%
2023 -70.090.000 100%
2024 -416.000 -16748.56%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Atea Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2018 -9.064.000
2019 -13.460.000 32.66%
2020 -10.864.000 -23.9%
2021 121.190.000 108.96%
2022 -115.909.000 204.56%
2023 -132.568.000 12.57%
2023 -135.956.000 2.49%
2024 -162.088.000 16.12%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Atea Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 0
2019 0 0%
2020 0 0%
2021 1 100%
2022 -1 200%
2023 -2 0%
2023 -2 0%
2024 -2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Atea Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -7.920.000
2019 -12.816.000 38.2%
2020 296.708.000 104.32%
2021 -87.009.000 441.01%
2022 -122.925.000 29.22%
2023 -85.395.000 -43.95%
2023 -17.591.000 -385.45%
2024 -42.202.000 58.32%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Atea Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -7.908.000
2019 -12.814.000 38.29%
2020 296.734.000 104.32%
2021 -87.005.000 441.05%
2022 -120.982.000 28.08%
2023 -85.395.000 -41.67%
2023 -17.591.000 -385.45%
2024 -42.202.000 58.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Atea Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 12.000
2019 2.000 -500%
2020 26.000 92.31%
2021 4.000 -550%
2022 1.943.000 99.79%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Atea Pharmaceuticals, Inc. Equity
Year Equity Growth
2018 -36.161.000
2019 -49.571.000 27.05%
2020 547.801.000 109.05%
2021 710.077.000 22.85%
2022 640.572.000 -10.85%
2023 581.730.000 -10.12%
2023 555.192.000 -4.78%
2024 476.470.000 -16.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Atea Pharmaceuticals, Inc. Assets
Year Assets Growth
2018 34.861.000
2019 22.073.000 -57.94%
2020 863.632.000 97.44%
2021 772.892.000 -11.74%
2022 666.708.000 -15.93%
2023 608.075.000 -9.64%
2023 594.968.000 -2.2%
2024 510.384.000 -16.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Atea Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2018 71.022.000
2019 71.644.000 0.87%
2020 315.831.000 77.32%
2021 62.815.000 -402.8%
2022 26.136.000 -140.34%
2023 26.345.000 0.79%
2023 39.776.000 33.77%
2024 33.914.000 -17.28%

Atea Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-2.09
Price to Earning Ratio
-1.63x
Price To Sales Ratio
0x
POCF Ratio
-2.36
PFCF Ratio
-2.37
Price to Book Ratio
0.6
EV to Sales
0
EV Over EBITDA
-0.23
EV to Operating CashFlow
-0.38
EV to FreeCashFlow
-0.38
Earnings Yield
-0.61
FreeCashFlow Yield
-0.42
Market Cap
0,29 Bil.
Enterprise Value
0,05 Bil.
Graham Number
16.3
Graham NetNet
5.56

Income Statement Metrics

Net Income per Share
-2.09
Income Quality
0.69
ROE
-0.33
Return On Assets
-0.34
Return On Capital Employed
-0.42
Net Income per EBT
1.01
EBT Per Ebit
0.86
Ebit per Revenue
0
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.44
Free CashFlow per Share
-1.44
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.43
Return on Tangible Assets
-0.34
Days Sales Outstanding
0
Days Payables Outstanding
4799.4
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.08
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
5,96
Book Value per Share
5,66
Tangible Book Value per Share
5.66
Shareholders Equity per Share
5.66
Interest Debt per Share
0.02
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.19
Current Ratio
19.02
Tangible Asset Value
0,48 Bil.
Net Current Asset Value
0,47 Bil.
Invested Capital
482369000
Working Capital
0,48 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Atea Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Atea Pharmaceuticals, Inc. Profile

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

CEO
Dr. Jean-Pierre Sommadossi Ph
Employee
75
Address
125 Summer Street
Boston, 02110

Atea Pharmaceuticals, Inc. Executives & BODs

Atea Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Wayne Foster CPA
Executive Vice President of Finance & Chief Accounting Officer
70
2 Ms. Jonae R. Barnes
Senior Vice President of Investor Relations & Corporate Communications
70
3 Mr. Ariyapadi N. Krishnaraj
Vice President of Marketing
70
4 Mr. Xiao-Jian Zhou Ph.D.
Executive Vice President of Early Stage Development
70
5 Mr. Adel Moussa Ph.D.
Executive Vice President of Chemistry
70
6 Dr. Janet M. J. Hammond M.D., Ph.D.
Chief Development Officer
70
7 Dr. Maria Arantxa Horga M.D.
Chief Medical Officer
70
8 Mr. John F. Vavricka
Chief Commercial Officer
70
9 Dr. Jean-Pierre Sommadossi Ph.D.
Founder, Chairman, Chief Executive Officer & President
70
10 Ms. Andrea J. Corcoran J.D.
Chief Financial Officer, Executive Vice President of Legal & Secretary
70

Atea Pharmaceuticals, Inc. Competitors